| Review and update of central serous chorioretinopathy. | |
| | |
MedLine Citation:
|
PMID: 21427570 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
PURPOSE OF REVIEW: Greater understanding of central serous chorioretinopathy (CSCR) has changed initial beliefs that CSCR is a benign condition affecting young men with almost complete resolution. CSCR has a spectrum of presentations with more diffuse retinal dysfunction and variations between races. CSCR can affect older individuals and in a subset of patients may lead to significant ocular morbidity. RECENT FINDINGS: Advances in imaging, particularly in indocyanine green angiography and optical coherence tomography, have led to a greater understanding of the pathophysiology of this condition. Treatments for CSCR are still evolving, in particular photodynamic dynamic therapy using lower doses and reduced fluence showing promising results. More research is required on ideal dosage. Anti-vascular endothelial growth factor treatment offers a new medical treatment modality with promising results. SUMMARY: There have been recent imaging developments in addition to therapeutic advances for refractory CSCR. |
| | |
Authors:
|
Alexander Ross; Adam H Ross; Quresh Mohamed |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-3-21 |
Journal Detail:
|
Title: Current opinion in ophthalmology Volume: - ISSN: 1531-7021 ISO Abbreviation: - Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-3-23 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9011108 Medline TA: Curr Opin Ophthalmol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Ophthalmology Department, Cheltenham General Hospital, Gloucestershire, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Varicocele repair: does it still have a role in infertility treatment?
Next Document: Preferred therapies for neovascular age-related macular degeneration.